Answers are grounded in this paper and cite their sources.
Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequency of headache than placebo in this 12-week trial. Injection-site reactions to the drug were common. The long-term durability and safety of fremanezumab require further study. (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT02621931 .).
No takes yet. Share an insight, caveat, or question.
Silberstein et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: